anti-DDR1 monoclonal antibody PRTH-101
Term · Oncology and biomedicine · MLC-T-ONC-010563
A humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against discoid domain receptor type 1 (DDR1), with potential immunomodulating and antineoplastic activities. Upon administration, anti-DDR1 monoclonal antibody PRTH-101 specifically targets, binds to and blocks DDR1, a protein expressed on tumor cells that binds collagen to make a minimally permeable physical barrier that blocks immune cells in the tumor microenvironment (TME) from interacting with and attacking the tumor. By blocking DDR1, PRTH-101 causes the collagen fibers lose alignment and loosen. This creates gaps in the tumor barrier, thereby allowing cytotoxic T-cells to enter and attack the tumor.
| Identifier | MLC-T-ONC-010563 |
|---|---|
| Field | Oncology and biomedicine |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-010563",
"term": "anti-DDR1 monoclonal antibody PRTH-101",
"field": "Oncology and biomedicine",
"definition": "A humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against discoid domain receptor type 1 (DDR1), with potential immunomodulating and antineoplastic activities. Upon administration, anti-DDR1 monoclonal antibody PRTH-101 specifically targets, binds to and blocks DDR1, a protein expressed on tumor cells that binds collagen to make a minimally permeable physical barrier that blocks immune cells in the tumor microenvironment (TME) from interacting with and attacking the tumor. By blocking DDR1, PRTH-101 causes the collagen fibers lose alignment and loosen. This creates gaps in the tumor barrier, thereby allowing cytotoxic T-cells to enter and attack the tumor.",
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/anti-ddr1-monoclonal-antibody-prth-101/"
}
Record 1,656 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.